MNV
Market News Video
MNV MNV 10 Stocks Crossing Below Book Value
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

First Week of ADAP April 17th Options Trading
Tuesday, March 10, 12:05 PM ET, by Market News Video Staff

Investors in Adaptimmune Therapeutics PLC (ADAP) saw new options become available this week, for the ...

ADAP Crosses Above Average Analyst Target
Wednesday, June 17, 7:33 AM ET, by Market News Video Staff

In recent trading, shares of Adaptimmune Therapeutics PLC (ADAP) have crossed above the average analyst ...

First Week of August 21st Options Trading For Adaptimmune Therapeutics (ADAP)
Monday, June 29, 10:38 AM ET, by Market News Video Staff

Investors in Adaptimmune Therapeutics PLC (ADAP) saw new options begin trading this week, for the ...

ADAP Crosses Above Average Analyst Target
Thursday, September 17, 8:13 AM ET, by Market News Video Staff

In recent trading, shares of Adaptimmune Therapeutics PLC (ADAP) have crossed above the average analyst ...

First Week of ADAP November 20th Options Trading
Monday, September 21, 11:12 AM ET, by Market News Video Staff

Investors in Adaptimmune Therapeutics PLC (ADAP) saw new options begin trading this week, for the ...

Adaptimmune Therapeutics is Now Oversold (ADAP)

By Market News Video Staff, Wednesday, October 21, 4:18 PM ET
Play Video: Learn About The RSI


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Wednesday, shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $4.52 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 51.7. A bullish investor could look at ADAP's 28.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ADAP shares:

Adaptimmune Therapeutics PLC 1 Year Performance Chart

Looking at the chart above, ADAP's low point in its 52 week range is $0.709 per share, with $13.40 as the 52 week high point — that compares with a last trade of $4.53. Find out what 9 other oversold stocks you need to know about »


Can your brain be trained to become a chart-predicting wizard? Click here to find out


This Article's Word Cloud:   ADAP   About   Adaptimmune   Buffett   Click   Find   Index   Know   Legendary   Looking   Oversold   Relative   Should   Start   Stocks   Strength   Therapeutics   Warren   Wednesday   about   above   advises   after   analysis   become   begin   below   brain   bullish   called   changing   chart   compares   comparison   fearful   greedy   investor   look   others   oversold   point   raquo   reading   share   shares   stock   that   week   when   with
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Stock Message Boards Stock Market Definitions
MNV

Adaptimmune Therapeutics is Now Oversold (ADAP) | Market News Video | Copyright © 2008 - 2021, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.